...
search icon
glpg-img

Galapagos NV ADR, Common Stock

GLPG

NSQ

$23.49

-$0.12

(-0.51%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.55B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
314.90K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.06
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$23.45 L
$40.34 H
$23.49

About Galapagos NV ADR, Common Stock

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGLPGSectorS&P500
1-Week Return-1.43%3.54%-0.58%
1-Month Return-13.96%7.51%1.89%
3-Month Return-18.32%-0.85%3.24%
6-Month Return-15.05%-1.67%10.09%
1-Year Return-38.7%5.2%22.09%
3-Year Return-65.17%13.08%35.68%
5-Year Return-89.8%44.4%83.47%
10-Year Return15.84%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue844.99M478.05M484.85M505.28M239.72M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":56.58,"profit":true},{"date":"2021-12-31","value":57.38,"profit":true},{"date":"2022-12-31","value":59.8,"profit":true},{"date":"2023-12-31","value":28.37,"profit":true}]
Cost of Revenue427.32M523.67M1.63M12.08M35.99M[{"date":"2019-12-31","value":81.6,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.31,"profit":true},{"date":"2022-12-31","value":2.31,"profit":true},{"date":"2023-12-31","value":6.87,"profit":true}]
Gross Profit417.67M(45.61M)483.22M493.20M203.74M[{"date":"2019-12-31","value":84.68,"profit":true},{"date":"2020-12-31","value":-9.25,"profit":false},{"date":"2021-12-31","value":97.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.31,"profit":true}]
Gross Margin49.43%(9.54%)99.66%97.61%84.99%[{"date":"2019-12-31","value":49.6,"profit":true},{"date":"2020-12-31","value":-9.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.94,"profit":true},{"date":"2023-12-31","value":85.27,"profit":true}]
Operating Expenses474.69M656.68M648.81M760.72M327.99M[{"date":"2019-12-31","value":62.4,"profit":true},{"date":"2020-12-31","value":86.32,"profit":true},{"date":"2021-12-31","value":85.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":43.12,"profit":true}]
Operating Income370.29M(178.63M)(165.60M)(267.52M)(88.26M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-48.24,"profit":false},{"date":"2021-12-31","value":-44.72,"profit":false},{"date":"2022-12-31","value":-72.25,"profit":false},{"date":"2023-12-31","value":-23.84,"profit":false}]
Total Non-Operating Income/Expense(214.17M)(146.01M)29.87M61.11M148.54M[{"date":"2019-12-31","value":-144.18,"profit":false},{"date":"2020-12-31","value":-98.3,"profit":false},{"date":"2021-12-31","value":20.11,"profit":true},{"date":"2022-12-31","value":41.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income150.06M(309.77M)(123.00M)(215.15M)5.63M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-206.43,"profit":false},{"date":"2021-12-31","value":-81.97,"profit":false},{"date":"2022-12-31","value":-143.37,"profit":false},{"date":"2023-12-31","value":3.75,"profit":true}]
Income Taxes214.00K1.23M2.42M2.84M9.61M[{"date":"2019-12-31","value":2.23,"profit":true},{"date":"2020-12-31","value":12.75,"profit":true},{"date":"2021-12-31","value":25.21,"profit":true},{"date":"2022-12-31","value":29.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes149.85M(311.00M)(125.42M)(217.99M)(3.99M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-207.55,"profit":false},{"date":"2021-12-31","value":-83.7,"profit":false},{"date":"2022-12-31","value":-145.48,"profit":false},{"date":"2023-12-31","value":-2.66,"profit":false}]
Income From Continuous Operations149.85M(311.00M)(125.42M)(217.99M)(153.07M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-207.55,"profit":false},{"date":"2021-12-31","value":-83.7,"profit":false},{"date":"2022-12-31","value":-145.48,"profit":false},{"date":"2023-12-31","value":-102.15,"profit":false}]
Income From Discontinued Operations1.16M5.57M22.19M--[{"date":"2019-12-31","value":5.21,"profit":true},{"date":"2020-12-31","value":25.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income149.84M(311.00M)(125.42M)(217.99M)211.70M[{"date":"2019-12-31","value":70.78,"profit":true},{"date":"2020-12-31","value":-146.91,"profit":false},{"date":"2021-12-31","value":-59.25,"profit":false},{"date":"2022-12-31","value":-102.97,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)2.18(4.68)(1.58)(3.32)3.25[{"date":"2019-12-31","value":67.18,"profit":true},{"date":"2020-12-31","value":-144.21,"profit":false},{"date":"2021-12-31","value":-48.69,"profit":false},{"date":"2022-12-31","value":-102.3,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GLPG
Cash Ratio 9.51
Current Ratio 10.13
Quick Ratio 9.95

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GLPG
ROA (LTM) -2.38%
ROE (LTM) -2.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GLPG
Debt Ratio Lower is generally better. Negative is bad. 0.31
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.69

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GLPG
Trailing PE NM
Forward PE 166.67
P/S (TTM) 5.98
P/B 0.52
Price/FCF NM
EV/R 1.18
EV/Ebitda NM
PEG NM

FAQs

What is Galapagos NV ADR share price today?

Galapagos NV ADR (GLPG) share price today is $23.49

Can Indians buy Galapagos NV ADR shares?

Yes, Indians can buy shares of Galapagos NV ADR (GLPG) on Vested. To buy Galapagos NV ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLPG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Galapagos NV ADR be purchased?

Yes, you can purchase fractional shares of Galapagos NV ADR (GLPG) via the Vested app. You can start investing in Galapagos NV ADR (GLPG) with a minimum investment of $1.

How to invest in Galapagos NV ADR shares from India?

You can invest in shares of Galapagos NV ADR (GLPG) via Vested in three simple steps:

  • Click on Sign Up or Invest in GLPG stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Galapagos NV ADR shares
What is Galapagos NV ADR 52-week high and low stock price?

The 52-week high price of Galapagos NV ADR (GLPG) is $40.34. The 52-week low price of Galapagos NV ADR (GLPG) is $23.45.

What is Galapagos NV ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Galapagos NV ADR (GLPG) is 0.52

What is the Market Cap of Galapagos NV ADR?

The market capitalization of Galapagos NV ADR (GLPG) is $1.55B

What is Galapagos NV ADR’s stock symbol?

The stock symbol (or ticker) of Galapagos NV ADR is GLPG

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top